Cargando…
Real-World Survival Outcomes Based on EGFR Mutation Status in Chinese Patients With Lung Adenocarcinoma After Complete Resection: Results From the ICAN Study
INTRODUCTION: The adjuvant treatment of patients with resected lung adenocarcinoma (LUAD) remains unstandardized. We analyzed the survival outcomes of these patients based on EGFR mutation status and adjuvant chemotherapy treatment. METHODS: This noninterventional real-world study (ICAN) enrolled Ch...
Autores principales: | Yang, Xue-Ning, Yan, Hong-Hong, Wang, Jun, Chu, Xiang-Yang, Liu, Zhi-Dong, Shen, Yi, Ma, Hai-Tao, Fu, Xiang-Ning, Hu, Jian, Zhou, Nai-Kang, Liu, Yong-Yu, Zhou, Xin-Ming, Li, Jing-Song, Yang, Kang, Li, Jian, Xu, Lin, Wang, Si-Yu, Wang, Qun, Liu, Lun-Xu, Xu, Shun, Chen, Zhong-Yuan, Lou, Hong-He, Wang, Chang-Li, Cheng, Ying, Liu, Si-Yang, Zhang, Xu-Chao, Zhong, Wen-Zhao, Wu, Yi-Long |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8683612/ https://www.ncbi.nlm.nih.gov/pubmed/34977823 http://dx.doi.org/10.1016/j.jtocrr.2021.100257 |
Ejemplares similares
-
ICan: An Integrated Co-Alteration Network to Identify Ovarian Cancer-Related Genes
por: Zhou, Yuanshuai, et al.
Publicado: (2015) -
The coexistence of MET over-expression and an EGFR T790M mutation is related to acquired resistance to EGFR tyrosine kinase inhibitors in advanced non-small cell lung cancer
por: Gou, Lan-Ying, et al.
Publicado: (2016) -
Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial
por: Zhong, Wen-Zhao, et al.
Publicado: (2021) -
Genomic signatures define three subtypes of EGFR-mutant stage II–III non-small-cell lung cancer with distinct adjuvant therapy outcomes
por: Liu, Si-Yang, et al.
Publicado: (2021) -
Concomitant genetic alterations having greater impact on the clinical benefit of EGFR‐TKIs in EGFR‐mutant advanced NSCLC than BIM deletion polymorphism
por: Liu, Si‐Yang, et al.
Publicado: (2020)